NEOGNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
NEOGEN CORP
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 7, 2026
$11.63−0.18 (-1.52%)
Close on Oct 19, 2026
- Market cap
- $2.54B
- P/E (TTM)
- –
- Dividend yield
- –
NEOGEN CORP revenue by segment
By business segment
| Revenue | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Food Safety | $166.80M | $156.70M | $165.55M | $152.05M | $161.80M | $152.80M | $164.24M | $159.35M | $166.87M | $157.75M | $164.40M | $166.28M | 74.0% | +3.1% |
| Animal Safety | $58.50M | $54.50M | $59.14M | $57.14M | $63.70M | $68.20M | $67.02M | $57.62M | $69.91M | $71.06M | $65.23M | $62.71M | 26.0% | -8.2% |
| Operating income | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Food Safety | $23.50M | $16.30M | $16.58M | $7.09M | -$586.10M | $19.30M | -$436.80M | $17.91M | $19.92M | $15.92M | $24.33M | $22.24M | -104.0% |
| Animal Safety | $5.50M | $5.70M | $8.83M | $4.47M | -$1.70M | $6.80M | -$362.00K | $2.59M | $8.42M | $14.78M | $7.74M | $8.36M | -423.5% |
By product or service
| Revenue | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product Revenues | $198.80M | $186.20M | $199.01M | $184.14M | $200.80M | $196.50M | $207.55M | $192.52M | $211.35M | $202.18M | $203.87M | $204.40M | 88.2% | -1.0% |
| Service Revenues | $26.50M | $25.00M | $25.69M | $25.05M | $24.70M | $24.50M | $23.71M | $24.45M | $25.42M | $26.63M | $25.76M | $24.59M | 11.8% | +7.3% |
By region
| Revenue | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| International | $115.00M | $108.90M | $114.26M | $107.12M | $113.00M | $105.60M | $117.50M | $112.58M | $120.42M | $104.59M | $116.08M | $117.92M | 51.0% | +1.8% |
| United States | $110.30M | $102.30M | $110.44M | $102.07M | $112.50M | $115.40M | $113.76M | $104.38M | $116.35M | $124.23M | $113.55M | $111.07M | 49.0% | -2.0% |
From the segment and revenue-disaggregation notes of Neogen's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.